{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/smoking-cessation/prescribing-information/bupropion/","result":{"pageContext":{"chapter":{"id":"029422cb-c063-54a5-adba-d7e2c1508a2c","slug":"bupropion","fullItemName":"Bupropion","depth":2,"htmlHeader":"<!-- begin field 904d2610-9bd5-4540-88eb-dc1c0856d1ea --><h2>Bupropion</h2><!-- end field 904d2610-9bd5-4540-88eb-dc1c0856d1ea -->","summary":"","htmlStringContent":"<!-- begin item 7a4d0acd-d977-48b6-b424-7a4c78bb1cbe --><!-- end item 7a4d0acd-d977-48b6-b424-7a4c78bb1cbe -->","topic":{"id":"ebf6cee5-5af1-52b6-be36-ffbde79ca62f","topicId":"d067f8f3-0954-4f6f-aa2d-7367538e4d66","topicName":"Smoking cessation","slug":"smoking-cessation","lastRevised":"Last revised in November 2020","chapters":[{"id":"0061c5ae-dd4a-5d21-b48c-668fde7b2792","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6d1d5418-f561-5af6-b8c6-fc662f3ed1a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4153a516-b9c3-5ccd-b0dc-802eec6e791e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8e76eb05-e3c6-56ff-9af2-254532c75b13","slug":"changes","fullItemName":"Changes"},{"id":"3c6ceb58-b810-5e70-839f-8509aaafe066","slug":"update","fullItemName":"Update"}]},{"id":"ea4cf1db-781d-5517-8878-d38a96f2d1c5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bbbe94e2-fe22-5d1a-acb7-68d5e9889beb","slug":"goals","fullItemName":"Goals"},{"id":"56f5ea28-1670-53a4-a478-33a402bc7d1b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"234b7e6d-ac08-55b2-abd7-674c4643c59c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d2e91021-4127-5bfa-9129-033bc40bcab8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0e030910-df21-55ed-85f4-778b0a92a88f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"583a3a07-c973-5d68-b342-99b8e0dbeb74","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8349892f-8857-507e-b3ca-b3aedf9ff29d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"22c82094-eeb9-578d-acb1-a91b122b264b","slug":"withdrawal-symptoms","fullItemName":"Withdrawal symptoms"},{"id":"684b949d-de54-55c1-9c8c-5e29f240784d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"de278e39-c963-55cb-b3f3-f4c21c4bce92","slug":"harms-caused-by-smoking","fullItemName":"Harms caused by smoking"},{"id":"a9f396cb-609a-5ab8-b6ad-24d7084af5f5","slug":"benefits-of-stopping-smoking","fullItemName":"Benefits of stopping smoking"}]},{"id":"d491264b-2fec-55fc-8464-dc497057057c","fullItemName":"Management","slug":"management","subChapters":[{"id":"67f11ceb-acb3-546c-ba55-c7981861e6bb","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"6593a229-0a53-5e7e-94df-52f7ea3e248d","slug":"adults","fullItemName":"Scenario: Adults"},{"id":"e616e0e0-2ef7-55fb-b0a5-40a1dee23996","slug":"pregnant-or-breastfeeding","fullItemName":"Scenario: Pregnant or breastfeeding"},{"id":"39b9fd08-1dfb-5cff-a105-6964621414fc","slug":"12-17-years","fullItemName":"Scenario: 12-17 years"},{"id":"1521b61b-1fc1-505a-b1ea-4f3c6c7821e5","slug":"harm-reduction","fullItemName":"Scenario: Harm reduction"}]},{"id":"534878c5-24a6-5d55-aab1-d680da731f9c","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5385fc41-730b-5f44-b19a-162c234ba090","slug":"nicotine-replacement-therapy-nrt","fullItemName":"Nicotine replacement therapy (NRT)"},{"id":"029422cb-c063-54a5-adba-d7e2c1508a2c","slug":"bupropion","fullItemName":"Bupropion"},{"id":"0bf318c3-08dc-5d92-a4d3-2a76e6dcacff","slug":"varenicline","fullItemName":"Varenicline"},{"id":"55631955-d4e3-58ea-92ab-c9beb61af299","slug":"drugs-affected-by-smoking-cessation","fullItemName":"Drugs affected by smoking cessation"}]},{"id":"08f5d42d-b8f6-5145-bef7-f1049e7b6e47","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4dd871a8-f5c2-5399-bbd0-e38843de9929","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"54db5fa3-0428-5365-9b73-16348c0cbc3f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7af0460f-945a-59a6-9b1a-583aab3c09b8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fe134945-3412-53ed-b798-57e958ac842c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d8a134c7-4e7c-5c14-a053-831f057b4fac","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"42f0adc0-ab3c-5a96-b5a6-0eb20614a611","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"07a973a1-96be-50d1-9ff8-17e6396e0d13","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"534878c5-24a6-5d55-aab1-d680da731f9c","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"f17e2fa2-1ed9-53ec-9cf2-727db34cb783","slug":"mode-of-action-of-bupropion","fullItemName":"Mode of action of bupropion","depth":3,"htmlHeader":"<!-- begin field 8c315c1e-e197-4283-9a80-018d168f1383 --><h3>Mode of action of bupropion</h3><!-- end field 8c315c1e-e197-4283-9a80-018d168f1383 -->","summary":"","htmlStringContent":"<!-- begin item 5a879ec8-c991-446d-bfce-ed72f64c7332 --><!-- begin field 4314e317-93cb-4134-9302-3c1476fe81aa --><ul><li>Bupropion is a relatively weak but selective dopamine and noradrenaline re-uptake inhibitor. Although the exact mechanism by which it aids smoking cessation is unclear, it is presumed to work directly on the brain pathways involved in addiction and withdrawal.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2017b</a>] </p><!-- end field 4314e317-93cb-4134-9302-3c1476fe81aa --><!-- end item 5a879ec8-c991-446d-bfce-ed72f64c7332 -->","subChapters":[]},{"id":"d62444d7-02d1-5f3d-8f45-de17acf04911","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 6443e54e-6e5e-44cc-b08e-ce4eca6b21c5 --><h3>Dose </h3><!-- end field 6443e54e-6e5e-44cc-b08e-ce4eca6b21c5 -->","summary":"","htmlStringContent":"<!-- begin item 699754f9-22a3-413b-bab7-fdd514f6fd01 --><!-- begin field 16bac2b9-c86f-4a93-89f3-dc8bcbecc39a --><ul><li>Bupropion should be started while the person is still smoking.<ul><li>Advise the person to stop smoking 7–14 days after starting bupropion.</li></ul></li><li>The dose of bupropion is 150 mg once a day for 6 days, increasing to 150 mg twice a day (doses at least 8 hours apart) for a total of 7–9 weeks.<ul><li>If no effect is seen after 7 weeks, discontinue treatment with bupropion.</li></ul></li><li>The lower dose of 150 mg once a day should be continued if the person:<ul><li>Is elderly.</li><li>Has mild to moderate hepatic impairment.</li><li>Has renal impairment (estimated glomerular filtration [eGFR] rate less than 50 mL/min).</li></ul></li><li>After the course is completed discontinuation reactions are unlikely and bupropion can be stopped without tapering the dose.<ul><li>However, if required, a tapering-off period can be considered. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">BNF 75, 2018</a>]</p><!-- end field 16bac2b9-c86f-4a93-89f3-dc8bcbecc39a --><!-- end item 699754f9-22a3-413b-bab7-fdd514f6fd01 -->","subChapters":[]},{"id":"2786c8ca-5a68-53a7-bda4-b79f9380af27","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 44f9e009-7b67-46f1-800e-af3cf1ad4baa --><h3>Contraindications and cautions</h3><!-- end field 44f9e009-7b67-46f1-800e-af3cf1ad4baa -->","summary":"","htmlStringContent":"<!-- begin item 8b7cab84-45b7-4c12-932b-d0cffb4541f4 --><!-- begin field 608b9c16-f7e3-467a-983f-6d185a99374e --><ul><li><strong>Do not prescribe bupropion to people </strong><strong>aged under 18 years, or people </strong><strong>with:</strong><ul><li>A current seizure disorder, or a history of seizures.</li><li>A central nervous system (CNS) tumour.</li><li>A current or previous diagnosis of bulimia or anorexia nervosa.</li><li>A history of bipolar disorder.</li><li>Severe hepatic cirrhosis.</li></ul></li><li><strong>Prescribe bupropion with caution in the elderly and to people with: </strong><ul><li>A predisposition to seizures. Risk factors include:<ul><li>Alcohol abuse.</li><li>A history of head trauma.</li><li>Diabetes.</li><li>Taking other drugs which lower the seizure threshold (for example, antipsychotics).</li><li>Use of stimulants or anorectic products.</li></ul></li><li>Hepatic impairment.</li><li>Renal impairment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">BNF 75, 2018</a>]</p><!-- end field 608b9c16-f7e3-467a-983f-6d185a99374e --><!-- end item 8b7cab84-45b7-4c12-932b-d0cffb4541f4 -->","subChapters":[]},{"id":"1fba2118-82d6-5859-9718-ce47635b1f4c","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7821b115-0691-4f97-a86f-d92cacac63a1 --><h3>Adverse effects </h3><!-- end field 7821b115-0691-4f97-a86f-d92cacac63a1 -->","summary":"","htmlStringContent":"<!-- begin item 45672fed-10fc-4711-ad58-1f07f63c6563 --><!-- begin field b83de13a-7cdf-4343-af21-f8806be263fa --><ul><li><strong>Adverse effects of bupropion include: </strong><ul><li><strong>Metabolism and nutrition</strong> — anorexia (uncommon).<ul><li><strong>Rarely: </strong>blood glucose disturbances, hyponatraemia.  </li></ul></li><li><strong>Psychiatric</strong> — insomnia (very common), depression, agitation, anxiety (common), confusion (uncommon). <ul><li><strong>Rarely or very rarely:</strong> irritability, hostility, hallucinations, depersonalisation, abnormal dreams including nightmares, delusions, aggression.</li></ul></li><li><strong>Nervous system</strong> — tremor, concentration disturbance, headache, dizziness, taste disorders (common).<ul><li><strong>Rarely:</strong> seizures, dystonia, ataxia, Parkinsonism, incoordination, memory impairment, paraesthesia, syncope.</li></ul></li></ul></li><li><strong>Other common adverse effects include: </strong><ul><li>Dry mouth, nausea, vomiting, abdominal pain, constipation.</li><li>Fever.</li><li>Hypersensitivity reactions (for example, urticaria).</li><li>Rash, pruritus, sweating.</li></ul></li><li><strong>Other rare adverse effects include: </strong><ul><li>Angioedema, dyspnoea/bronchospasm, anaphylactic shock.</li><li>Arthralgia, myalgia.</li><li>Erythema multiforme, Stevens-Johnson syndrome.</li><li>Palpitations.</li><li>Urinary frequency/retention.</li><li>Vasodilation, postural hypotension.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">BNF 75, 2018</a>]</p><!-- end field b83de13a-7cdf-4343-af21-f8806be263fa --><!-- end item 45672fed-10fc-4711-ad58-1f07f63c6563 -->","subChapters":[]},{"id":"cdb0baa5-fa46-58ae-8a0b-40e6f3310d80","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 223e395e-284d-4af6-adaa-6d7a0488da8a --><h3>Drug interactions</h3><!-- end field 223e395e-284d-4af6-adaa-6d7a0488da8a -->","summary":"","htmlStringContent":"<!-- begin item 962ebdfa-f7cb-4e79-87c6-451c98af77d5 --><!-- begin field 500dbb54-fb83-46e2-8481-9c230b6b4583 --><ul><li><strong>Drug interactions may occur if bupropion is taken concurrently with: </strong><ul><li><strong>Benzodiazepines</strong> — concurrent use is contraindicated when withdrawing benzodiazepines (or any other drug associated with seizures on withdrawal).</li><li><strong>Carbamazepine, phenytoin, phenobarbital, and primidone </strong>— monitor for evidence of reduced efficacy of bupropion (most likely) and/or increased toxicity (due to raised metabolite). Note that bupropion is contraindicated in people with current or past seizure disorders.</li><li><strong>Flecainide </strong>— levels may be increased if taken concurrently with bupropion. Reduce the dose of flecainide if required. </li><li><strong>HIV protease inhibitors</strong> (ritonavir) — levels of bupropion are reduced. Start bupropion at the recommended dose and titrate as required. </li><li><strong>Levodopa </strong>— monitor carefully for increased toxicity of levodopa.</li><li><strong>Monoamine oxidase inhibitor (MAOI) </strong>— bupropion toxicity may be enhanced if taken concurrently with an MAOI, leading to severe hypertension. Concurrent us is contraindicated and for two weeks after stopping an MAOI.<ul><li>For moclobemide (a reversible MAOI), this period can be reduced to 24 hours.</li></ul></li><li><strong>Sodium valproate </strong>— monitor for evidence of increased bupropion toxicity (due to increased levels of an active metabolite) or sodium valproate toxicity, as high-dose bupropion may increase valproate levels. Note that bupropion is contraindicated in people with current or past seizure disorders.</li><li><strong>Tamoxifen</strong> — concurrent use with bupropion may reduce the metabolism of tamoxifen to one of its active metabolites. Avoid concurrent use. </li><li><strong>Selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRIs)</strong> — risk of serotonin syndrome if taken concurrently with bupropion. If concurrent treatment is required, monitor for adverse effects, particularly when initiating treatment of increasing doses.</li><li><strong>Other drugs known to lower the seizure threshold </strong>— concurrent use with bupropion will increase the likelihood of seizures. A maximum dose of 150 mg is recommended when taken with drugs that lower the seizure threshold, including: <ul><li>Antipsychotics (risperidone, thioridazine).</li><li>Antidepressants (fluoxetine, paroxetine, and sertraline).</li><li>Antimalarials (mefloquine).</li><li>Aminophylline, theophylline.</li><li>Corticosteroids.</li><li>Quinolones (ciprofloxacin, ofloxacin).</li><li>Sedating antihistamines (chlorphenamine, clemastine).</li><li>Tramadol.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2020</a>]</p><!-- end field 500dbb54-fb83-46e2-8481-9c230b6b4583 --><!-- end item 962ebdfa-f7cb-4e79-87c6-451c98af77d5 -->","subChapters":[]},{"id":"67a41458-5341-5826-98b8-68c5a3538f15","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field e52bd2f1-d2cf-4757-9ac5-a8a901064989 --><h3>Monitoring</h3><!-- end field e52bd2f1-d2cf-4757-9ac5-a8a901064989 -->","summary":"","htmlStringContent":"<!-- begin item 67a6b832-676c-42e2-bae1-a8a9010648d2 --><!-- begin field 32f8cdd2-4095-4ff2-98fb-a8a901064989 --><ul><li>The manufacturer recommends that a baseline blood pressure (BP) should be measured at the start of treatment and monitored during treatment, especially in people with pre-existing hypertension.</li><li>If there is a clinically relevant increase in BP, bupropion should be stopped.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">BNF 75, 2018</a>]</p><!-- end field 32f8cdd2-4095-4ff2-98fb-a8a901064989 --><!-- end item 67a6b832-676c-42e2-bae1-a8a9010648d2 -->","subChapters":[]},{"id":"708bd4ff-dac5-57e1-8de2-bc230501b2a1","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 97af93aa-b343-4bbc-b344-a8a901060586 --><h3>Pregnancy and breastfeeding</h3><!-- end field 97af93aa-b343-4bbc-b344-a8a901060586 -->","summary":"","htmlStringContent":"<!-- begin item a22107ad-d1d3-4626-b691-a8a90106047b --><!-- begin field 45f0ffe3-a7d2-488a-9627-a8a901060586 --><h4>Pregnancy</h4><ul><li>Bupropion should be avoided in women who are pregnant.</li></ul><h4>Breastfeeding</h4><ul><li>Bupropion and its active metabolites are excreted in breastmilk.<ul><li>Bupropion should be avoided in women who are breastfeeding.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">ABPI, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/smoking-cessation/references/\">BNF 75, 2018</a>]</p><!-- end field 45f0ffe3-a7d2-488a-9627-a8a901060586 --><!-- end item a22107ad-d1d3-4626-b691-a8a90106047b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}